- The use of an aromatase inhibitor (letrozole) with an inhibitor of the cyclin dependent kinases 4 and 6 (ribociclib):
- Was compared with aromatase inhibitor alone in postmenopausal women with hormone receptor positive, HER2-negative metastatic breast cancer:
- In the MONALEESA-2 study:
- Results showed an improvement in:
- Progression-free survival (PFS):
- From 42.2% to 63%
- Overall response rate:
- From 37.1% to 52.7%
- With the addition of ribociclib to letrozole alone
- From 37.1% to 52.7%
- Progression-free survival (PFS):
- Results showed an improvement in:
- In the MONALEESA-2 study:
- Was compared with aromatase inhibitor alone in postmenopausal women with hormone receptor positive, HER2-negative metastatic breast cancer:
- This regimen was also investigated in pre menopausal women with advanced, hormone receptor-positive breast cancer:
- Improved PFS compared with placebo plus endocrine therapy
- References:
- Hortobagi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18)1738-1748.
- Tripathy D, Im SA2, Colleoni M3, Franke F4, Bardia A5, Harbeck Nm et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904-915.
#Arrangoiz #CancerSurgeon #BreastSurgeon #BreastCancer #Monaleesa2 #Ribociclib #CASO #CenterforADvancedSurgicalOncology
Rodrigo Arrangoiz MS, MD, FACS, FSSO 